High take-up reported of Novartis' Cosentyx in psoriatic arthritis
US rheumatologists are increasingly adopting Swiss pharma major Novartis’ (NOVN: VX) interleukin (IL)-17 inhibitor, Cosentyx (secukinumab), into their treatment algorithm for psoriatic arthritis (PsA), according to a quarterly report.
Insights from 100 American rheumatologists are part of the RealTime Dynamix: Psoriatic Arthritis report providing brand insights on the PsA market, one of the features of which is their take on the early adoption and success of Cosentyx.
The US Food and Drug Administration approved the use of Cosentyx for PsA in January of this year and the rheumatologists asked for the report have revealed that there are high levels of satisfaction and excitement about the results that their patients are achieving with the latest biologic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze